Novate News

Novate Filter Yields Zero Pulmonary Embolisms at 12 Months

Galway, Ireland – 12 September 2017.  Clinical trial results for Novate’s SENTRY device have been presented by Principal Investigator, Michael Dake MD of Stanford University in California at the 15th Annual Conference on Vascular Interventional Advances (VIVA17), which has been taking place this week in Las Vegas, Nevada, USA.

SENTRY is a prospective, single-arm, multi-centre registry trial in which the safety and effectiveness of the world’s first bioconvertible inferior vena cava (IVC) filter was studied.  The SENTRY is a new generation of IVC filter designed to provide protection from pulmonary embolism (PE) for the period of transient risk and then bioconvert to leave a patent, unobstructed IVC lumen, obviating the need to retrieve and addressing the typical filter-related complications of existing IVC filters.

129 patients requiring temporary protection against PE were enrolled across 23 sites in the US, Europe and Chile.  The rate of new symptomatic PE through 12 months was 0% (0/129).  There were no instances of filter tilting, migration, embolization, fracture, or IVC perforation through 12 months, and there were no filter-related deaths.   The rate of successful filter bioconversion was 95.7% (110/115) at 6 months and 96.4% (106/110) at 12 months.  This is higher than the majority of published IVC filter retrieval rates.  The Sentry IVC filter received U.S. FDA510(k) clearance in February 2017.

Principal Investigator, Dr Dake, commented “The SENTRY 1yr results are compelling, a 0% PE rate and no filter-related complications show that the Sentry IVC filter represents an important new development in the prevention of PE.”

Paul Bateman, CEO of Seroba’s investee company Novate,  added “We are enormously grateful to Dr Dake and all of the SENTRY investigational teams for their contribution to such a significant study.  These data for this new generation of IVC filter marks a paradigm shift in the prevention of PE.”

About Novate Medical

Based in Galway, Ireland, Novate Medical has developed Sentry, the world’s first bioconvertible inferior vena cava (IVC) filter for the prevention of pulmonary embolism (PE) in patients at transient PE risk.  The Sentry IVC filter does not require retrieval and addresses many of the known complications associated with currently available devices.

For further information: Vicky La Touche-Price at Seroba Life Sciences on +353 (0)1 6334028.

Recent Articles

Home V2

Seroba Invests in Storm Therapeutics

20 May 2019.  STORM Therapeutics (“STORM”), the drug discovery company tackling disease through modulating RNA modifying enzymes, has announced that […]

Read More
Quanta SC+

Quanta SC+ confirmed as safe and easy to use

Alcester, Warwickshire, UK, 15 April 2019.  Seroba’s portfolio company, Quanta Dialysis Technologies Ltd (“Quanta” or the “Company”), a pioneering medical […]

Read More
Fusion

Fusion Raises $105m in Series B Financing

April 2nd 2019. Hamilton, Canada and Dublin, Ireland.  Seroba’s portfolio company, Fusion Pharmaceuticals, a clinical-stage biopharmaceutical company developing targeted alpha-particle […]

Read More
Jen Moderator Session On Investment Cycles

VCs with €6Bn in Funds to Invest Visit Dublin

The sixth annual MedTech Strategist Innovation Summit Dublin will take place this April in the Shelbourne Hotel. Dozens of Venture […]

Read More
T: 353 (0)1 633 4028

18 Herbert Street
Dublin 2
D02 FK19
Ireland

Scroll to Top